Dr Stewart Abbot
Stewart Abbot is the Chief Development Officer at Fate Therapeutics (fatetherapeutics.com). He holds a B.Sc. in Biological Sciences (Edinburgh), M.Sc. in Biomedical Engineering (Glasgow) and Ph.D. in Pathology (London). His academic career focused on basic and translational science initiatives in vascular biology, pharmacology and toxicology. He joined Amersham Biosciences in 2000 and developed Amersham’s and, following acquisition, General Electric’s stem cell-based drug screening capabilities. He was head of the Molecular and Cellular Biology research laboratory at GE’s Global Research Center from 2004-2007. In 2007 he joined Celgene to develop novel cell-based therapeutic candidates and subsequently development of external R&D collaborations and alliances. He joined Fate in July 20015 and his current role oversees all aspects of translational research and development of hematopoietic and induced pluripotent cell-based immunotherapeutics at Fate Therapeutics.